Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Sellas Life Sciences Group
Merck Sharp & Dohme LLC
AvenCell Therapeutics, Inc.
Caribou Biosciences, Inc.
Tempus AI
Gamida Cell ltd
Ascentage Pharma Group Inc.
Pfizer
Incyte Corporation
AbbVie
Orca Biosystems, Inc.
Pfizer
CellCentric Ltd.
BeOne Medicines
Kura Oncology, Inc.
Incyte Corporation
Sichuan Baili Pharmaceutical Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Biotroy Therapeutics
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Indapta Therapeutics, INC.
Cogent Biosciences, Inc.
Tr1X, Inc.
JaxBio Ltd
Hangzhou Sumgen Biotech Co., Ltd.
AbbVie
Ipsen
Munich Leukemia Laboratory
Takeda
Vincerx Pharma, Inc.
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
AbbVie
Mundipharma Research Limited
Kyowa Kirin Co., Ltd.
MitoImmune Therapeutics
Pack Health
Newave Pharmaceutical Inc
Shenzhen TargetRx, Inc.
Prelude Therapeutics
Sumitomo Pharma America, Inc.
Bellicum Pharmaceuticals
AstraZeneca
Fate Therapeutics
Karyopharm Therapeutics Inc
AbbVie
Molecular Templates, Inc.
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
iCell Gene Therapeutics